Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA

Tocilizumab is a humanized anti–interleukin‐6 receptor antibody for treating rheumatoid arthritis. Pharmacokinetic/pharmacodynamic analysis was performed on the 24‐week double‐blind parts of 2 randomized, controlled trials: SUMMACTA and BREVACTA. SUMMACTA compared subcutaneous tocilizumab 162 mg eve...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdallah, Hisham, Hsu, Joy C., Lu, Peng, Fettner, Scott, Zhang, Xiaoping, Douglass, Wendy, Bao, Min, Rowell, Lucy, Burmester, Gerd R., Kivitz, Alan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Pharmacokinetics/Pharmacodynamics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363244/
https://www.ncbi.nlm.nih.gov/pubmed/27599663
http://dx.doi.org/10.1002/jcph.826

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363244/
https://www.ncbi.nlm.nih.gov/pubmed/27599663
http://dx.doi.org/10.1002/jcph.826

Ejemplares similares